keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tirzepatide TFA (LY3298176 TFA), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is under development for type 2 diabetes treatment [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Tirzepatide TFA (LY3298176 TFA), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, is under development for type 2 diabetes treatment [1]. |
Synonyms | Tirzepatide TFA(2023788-19-2 free base), LY3298176 TFA |
Molecular Weight | 4927.47 |
Formula | C227H349F3N48O70 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tirzepatide TFA Tirzepatide TFA(2023788-19-2 free base) LY3298176 TFA inhibitor inhibit